EBITDA Margin % is calculated as EBITDA divided by its Revenue. Fortress Biotech's EBITDA for the
three
months ended in Mar. 2026 was $145.28 Mil. Fortress Biotech's Revenue for the
three
months ended in Mar. 2026 was $16.04 Mil. Therefore, Fortress Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 905.85%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fortress Biotech EBITDA Margin % Related Terms
Fortress Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Fortress Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FBIO vs PTHS, IBIO, NRXS: EBITDA Margin % Comparison
For the Biotechnology subindustry, Fortress Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (FBIO) has a EBITDA Margin % of 905.85% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fortress Biotech and its competitors. According to the industry distribution chart, Fortress Biotech ranks #12 out of 945 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Fortress Biotech's EBITDA Margin % too high?
Fortress Biotech's current EBITDA Margin % is 905.85%. Based on the distribution chart, Fortress Biotech ranks #12 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's EBITDA Margin % compare to PTHS and IBIO?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #12 out of 945 companies for EBITDA Margin %. This places Fortress Biotech in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current EBITDA Margin % is 905.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.23, compared to a current price of $3.14 — trading 155.3% above its estimated fair value. The current EBITDA Margin % is 905.85%. Fortress Biotech's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current EBITDA Margin % is 905.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (FBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of $3.14 is trading 155.3% above its estimated GF Value™ of $1.23.
GuruFocus considers Fortress Biotech to be Significantly Overvalued.
Key valuation signals for FBIO:
EBITDA Margin %: 905.85%
GF Value™: $1.23 vs. price of $3.14 (155.3% above fair value)
No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score
Get the complete analysis for FBIO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FBIO has been successfully added to your 
